공지사항

Lung Cancer - Leading Cause of Death in Canada

Lung cancer is Canada's most frequent cause of death. Previous studies through the International Cancer Benchmarking Partnership have revealed that it is a challenge to get an accurate diagnosis, as evidenced by a range of times ranging from 28-87 days from the time of referral to treatment initiation in countries that have similar access to healthcare as Canada. Access to timely assessments, organized system of triage and referral, and communication between HCPs and patients are vital for optimizing care pathways.

Risk Factors

Certain factors can increase your risk of developing canadian pacific interstitial lung disease cancer. Certain factors, like smoking cigarettes, can't be altered. Others, like the family history or age, cannot be changed. Risk factors can help doctors predict the likelihood of developing a specific disease. A risk factor doesn't mean that you'll get the disease. Many people develop cancer without having any risk factors.

Lung cancer is the most frequent type of cancer in Canada and is the most frequent cause of cancer deaths. The majority of people diagnosed with non-small cell lung cancer (NSCLC) have advanced stage cancer at the time of diagnosis. The aim of Canadian pacific acute lymphocytic Leukemia-R is to improve patient outcomes through the development of a more precise, evidence-based staging system for NSCLC. This system will enable physicians to identify patients with early stage disease that are likely to respond to therapy and those who may not to, so that the right treatment can be started earlier.

Most lung cancer cases are diagnosed in people 60 years and older. Factors that can increase the chance of a lung cancer diagnosis include smoking in the past or currently asbestos exposure, and an ancestor with a history of the disease. People who are at an increased risk of developing cancer in the lung should take a regular low-dose CT screening to identify early stage cancer. However, this screening is not currently available in all provinces.

Diagnosis

Lung cancer is the most common cause of death from cancer in Canada. It is one of the most treatable tumors when found early. According to guidelines issued by the Nordic countries and canadian pacific acute Lymphocytic leukemia Cancer Care Ontario, diagnostic treatment should be carried out within 28 day of referral and Canadian pacific acute lymphocytic leukemia treatment must begin in 65% of cases [2525. In the COVID-19 pandemic, the diagnosis of lung cancer is more difficult due to the reallocation of resources and staff to manage the rise in COVID-19 cases, restrictions on aerosol-generating tests, and confusion regarding the symptoms of lung cancer and those of the pandemic.

Treatment

Lung cancer continues to be a major cause of cancer death in Canada. An early diagnosis and access to curative treatment options are key. It is essential to assess and improve care pathways in order to provide patients with the best chance at surviving cancer [1,21. In the first phase of treatment, it is important to have timely assessments, triage processes, referrals, and a good communication between HCPs as well as allied healthcare professionals, and other healthcare professionals.

Additionally, a functioning multidisciplinary team is essential for the successful management of advanced lung cancer. It is crucial to have a physician experienced in EBUS and CT bronchoscopy, aswell as a radiation specialist with expertise in administering radiotherapy to the chest. A regional lung cancer screening program is also recommended to aid in the early detection.

A recent study of benchmarking across all jurisdictions found that many jurisdictions struggled to meet guidelines that recommend that diagnosis workup be completed within 28 days of referral, and that treatment begin within 42 days following CCRRT. This delay is usually attributed to a lack of resources, such as PET CT equipment triage protocols for suspected patients as well as long wait times for imaging appointments.

Durvalumab has been proven to be safe in application. The 2-year rwPFS was comparable to the canadian pacific pulmonary fibrosis study (despite excluding PS >1 while canadian pacific kidney cancer only included PS 0, 1 or 0). While durvalumab was generally tolerated with no adverse effects, pneumonitis as well as ILD resulted in treatment discontinuation in 9.5 percent of patients. Further study is required to determine if the toxicities can be avoided by modifying the regimen and/or patient selection.